Sign In
Buy AXNX
$70.98
+0 (+0%)
At Close: Feb 13, 2025
Axonics (AXNX) Soars 7.4%: Is Further Upside Left in the Stock?
09:15am, Friday, 07'th Jan 2022
Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
11:00am, Thursday, 06'th Jan 2022 Kwhen FinanceAxonics, Inc. (AXNX) CEO Raymond Cohen on Q3 2021 Results - Earnings Call Transcript
12:58am, Sunday, 07'th Nov 2021
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q3 2021 Results - Earnings Call Transcript
Axonics® Provides Additional Update on Inter Partes Review Proceedings
06:08pm, Wednesday, 22'nd Sep 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
U.S. Patent and Trademark Office Rejects Axonics' Challenge to Medtronic Patents
05:29pm, Monday, 13'th Sep 2021
DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its inte
Axonics® Announces Partial Decision on Inter Partes Review Proceedings
05:19pm, Monday, 13'th Sep 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics: Buy at the High?
06:12am, Thursday, 02'nd Sep 2021
Axonics' stock price just hit its 52-week high, but its momentum means it's unlikely to last.
Axonics® to Participate in Upcoming Investor Conferences
06:00am, Friday, 27'th Aug 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics, Inc.'s (AXNX) CEO Raymond Cohen on Q2 2021 Results - Earnings Call Transcript
12:29pm, Sunday, 08'th Aug 2021
Axonics, Inc.'s (AXNX) CEO Raymond Cohen on Q2 2021 Results - Earnings Call Transcript
Axonics® Reports Second Quarter 2021 Financial Results
04:01pm, Thursday, 05'th Aug 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics® Announces Appointment of Dr. Esteban López to its Board of Directors
06:00am, Thursday, 15'th Jul 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics® to Report Second Quarter 2021 Financial Results on August 5, 2021
06:00am, Thursday, 08'th Jul 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics® Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator
04:01pm, Thursday, 24'th Jun 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics® Receives FDA Approval Further Expanding MRI Labeling
06:00am, Thursday, 20'th May 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters' Option to Purchase Additional Stock
04:05pm, Friday, 14'th May 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder a
